BlackRock, Inc. 13D and 13G filings for Crinetics Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-01-25 4:59 pm Purchase |
2023-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
BLACKROCK INC BLK |
5,345,114 8.000% |
1,427,625 (+36.44%) |
Filing |
| 2023-01-31 1:58 pm Purchase |
2022-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
BLACKROCK INC BLK |
3,917,489 7.300% |
641,319 (+19.58%) |
Filing |
| 2022-02-03 4:41 pm Purchase |
2021-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
BLACKROCK INC BLK |
3,276,170 6.900% |
1,162,975 (+55.03%) |
Filing |
| 2021-02-02 3:13 pm Purchase |
2020-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
BLACKROCK INC BLK |
2,113,195 6.400% |
2,113,195 (New Position) |
Filing |